Radiodermatitis. Malignant neoplasm of breast, Acute radiodermatitis
Conditions
Interventions
Intervention 1: Patients undergoing radiotherapy will receive celecoxib capsules containing BD. Intervention 2: Patients undergoing radiotherapy will receive placebo capsules containing lactose,BD.
Treatment - Drugs
Placebo
Patients undergoing radiotherapy will receive celecoxib capsules containing BD.
Patients undergoing radiotherapy will receive placebo capsules containing lactose,BD.
Sponsors
Vice Chancellor for Research and Technology, Mazandaranl University of Medical Scenices
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria; Adults over 18 years and less 70 years; breast cancer;about 50Gy total dose of radiation.Exclusion criteria:Smoking; sing the anti-inflammatory drug such as dexametasone and NSAID, active skin infection and dermatitis; using any topical products on breast; the disease weakens related to the immune system and a lack of diabetes that affected on wound healing; diseases related to kidney and liver.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of radiation-induced skin toxicity (such as Erythema, dry desquamation, itching, and ulcer). Timepoint: Just before drug treatment and then weekly for end of radiotehrapy. Method of measurement: According to RTOG scoring system with a questionnair. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed Jalal Hosseinimehr
Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences
Outcome results
None listed